Authors

Latest:

Dr. DiNome on Surgical Approaches in Patients With Breast Cancer

Maggie DiNome, MD, associate professor of surgery, University of California, Los Angeles Medical Center, discusses the evolution of surgical approaches in patients with breast cancer.

Maha H. Hussain, MB ChB

Latest:

Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.

Maha H. Hussain, MD, FACP

Latest:

Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Maha Hussain, MD, FACP

Latest:

Dr. Hussain on Retrospective Analysis of the ARASENS trial in mHSPC

Maha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.

Maha Hussain, MD, FACP, FASCO

Latest:

Dr. Hussain on Meaningful Effect as an End Point in Prostate Cancer Trials

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Maisam Fazel, FRCS, MS, MB BChir

Latest:

Dr. Fazel on Trends in Surgical Training

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

Major Lindsey Graham, MD, MC, US Army

Latest:

A Day in the Life of a Military Hematology/ Oncology Fellow

At 5:45 am, the alarm on my phone goes off. I have 20 minutes until my 2 boys wake up, which is just enough time to get ready for work and fix myself a cup of coffee.

Maki Tanioka, MD, PhD

Latest:

Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast Cancer

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Malcolm DeCamp, MD

Latest:

Dr. DeCamp on Platforms of Surgical Management in Lung Cancer

Malcolm McAvoy DeCamp, Jr, MD, chief of Thoracic Surgery in the Department of Surgery, Northwestern University Feinberg School of Medicine, discusses different platforms of surgical management in the treatment of patients with lung cancer.

Malcolm Mason, MD

Latest:

Dr. Mason on Next Steps Following 10-Year PROTECT Study Data in Prostate Cancer

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses next steps following the 10-year PROTECT study data for patients with prostate cancer.

Malcolm Ross, MD

Latest:

Dr. Ross on the Unmet Needs in Uterine Carcinosarcoma

Malcolm Ross, MD, University of Pittsburgh, discusses unmet needs for patients with uterine carcinosarcoma.

Malcom Mason, MD

Latest:

Dr. Mason on the Significant Results from the PROTECT Study in Prostate Cancer

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Malini Harigopal, MD

Latest:

Dr. Harigopal on Advances With Breast Cancer Pathology

Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.

Manali Bhave, MD

Latest:

Sequencing Antibody-Drug Conjugates (ADCs) in HR+/HER2-Low Metastatic Breast Cancer

Laura Spring, MD, and Manali Bhave, MD, discuss sequencing approved antibody-drug conjugates, T-DM1 and sacituzumab govitecan, for hormone receptor-positive, HER2-low metastatic breast cancer after progression on chemotherapy.

Manfred Welslau, MD

Latest:

Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab Biosimilar

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Manish A. Shah, MD

Latest:

Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

Manish A Shah, MD, Weill Cornell Medicine

Manish A. Shah, MD, Weill Cornell Medicine, New York-Presbyterian Hospital

Manish Kohli, MD

Latest:

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Manish R. Patel, DO

Latest:

Dr. Patel on Key Updates from First-Line Trials in NSCLC

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.